Acta Pharmaceutica Sinica. B最新文献

M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy 通过基因疗法和癌症免疫疗法的杂交增强癌症治疗的 M1 极化巨噬细胞衍生细胞纳米囊包覆脂质纳米粒子

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.004

Ha Eun Shin , Jun-Hyeok Han , Seungyong Shin , Ga-Hyun Bae , Boram Son , Tae-Hyung Kim , Hee Ho Park , Chun Gwon Park , Wooram Park

{"title":"M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy","authors":"Ha Eun Shin , Jun-Hyeok Han , Seungyong Shin , Ga-Hyun Bae , Boram Son , Tae-Hyung Kim , Hee Ho Park , Chun Gwon Park , Wooram Park","doi":"10.1016/j.apsb.2024.03.004","DOIUrl":"10.1016/j.apsb.2024.03.004","url":null,"abstract":"<div><p>Optimum genetic delivery for modulating target genes to diseased tissue is a major obstacle for profitable gene therapy. Lipid nanoparticles (LNPs), considered a prospective vehicle for nucleic acid delivery, have demonstrated efficacy in human use during the COVID-19 pandemic. This study introduces a novel biomaterial-based platform, M1-polarized macrophage-derived cellular nanovesicle-coated LNPs (M1-C-LNPs), specifically engineered for a combined gene-immunotherapy approach against solid tumor. The dual-function system of M1-C-LNPs encapsulates <em>Bcl2</em>-targeting siRNA within LNPs and immune-modulating cytokines within M1 macrophage-derived cellular nanovesicles (M1-NVs), effectively facilitating apoptosis in cancer cells without impacting T and NK cells, which activate the intratumoral immune response to promote granule-mediating killing for solid tumor eradication. Enhanced retention within tumor was observed upon intratumoral administration of M1-C-LNPs, owing to the presence of adhesion molecules on M1-NVs, thereby contributing to superior tumor growth inhibition. These findings represent a promising strategy for the development of targeted and effective nanoparticle-based cancer genetic-immunotherapy, with significant implications for advancing biomaterial use in cancer therapeutics.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524000856/pdfft?md5=a915345e358d4968a525aeaeabc62a90&pid=1-s2.0-S2211383524000856-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140125683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycnsisitin A: A promising bicyclic peptide against heart failure that facilitates TFRC-mediated uptake of iron in cardiomyocytes 甘草次苷 A：一种有望防治心力衰竭的双环肽，可促进 TFRC 介导的心肌细胞铁吸收

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.02.026

Jichao Zhou , Yuanyuan Liu , Xiaoli Wei , Meng Yuan , Xu Zhang , Lingfeng Qin, Bing Cui, Pingping Li, Jing Zhang, Ziming Feng, Jianshuang Jiang, Xiang Yuan, Ruibing Xu, Zhimeng Zhang, Peicheng Zhang, Xiaowei Zhang, Yanan Yang

{"title":"Glycnsisitin A: A promising bicyclic peptide against heart failure that facilitates TFRC-mediated uptake of iron in cardiomyocytes","authors":"Jichao Zhou , Yuanyuan Liu , Xiaoli Wei , Meng Yuan , Xu Zhang , Lingfeng Qin, Bing Cui, Pingping Li, Jing Zhang, Ziming Feng, Jianshuang Jiang, Xiang Yuan, Ruibing Xu, Zhimeng Zhang, Peicheng Zhang, Xiaowei Zhang, Yanan Yang","doi":"10.1016/j.apsb.2024.02.026","DOIUrl":"10.1016/j.apsb.2024.02.026","url":null,"abstract":"<div><p>Zhigancao decoction is a traditional prescription for treating irregular pulse and palpitations in China. As the monarch drug of Zhigancao decoction, the bioactive molecules of licorice against heart diseases remain elusive. We established the HRESIMS-guided method leading to the isolation of three novel bicyclic peptides, glycnsisitins A–C (<strong>1</strong>–<strong>3</strong>), with distinctive C–C and C–O–C side-chain-to-side-chain linkages from the roots of <em>Glycyrrhiza uralensis</em> (Licorice). Glycnsisitin A demonstrated stronger cardioprotective activity than glycnsisitins B and C in an <em>in vitro</em> model of doxorubicin (DOX)-induced cardiomyocyte injury. Glycnsisitin A treatment not only reduced the mortality of heart failure (HF) mice in a dose-dependent manner but also significantly attenuated DOX-induced cardiac dysfunction and myocardial fibrosis. Gene set enrichment analysis (GSEA) of the differentially expressed genes indicated that the cardioprotective effect of glycnsisitin A was mainly attributed to its ability to maintain iron homeostasis in the myocardium. Mechanistically, glycnsisitin A interacted with transferrin and facilitated its binding to the transferrin receptor (TFRC), which caused increased uptake of iron in cardiomyocytes. These findings highlight the key role of bicyclic peptides as bioactive molecules of Zhigancao decoction for the treatment of HF, and glycnsisitin A constitutes a promising therapeutic agent for the treatment of HF.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524000790/pdfft?md5=815a57dc80f256fde8e0a4f5d315f2bb&pid=1-s2.0-S2211383524000790-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140046316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma 细胞周期蛋白 D1 降解中断导致套细胞淋巴瘤的发生

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.013

Ke Lu , Ming Zhang , Hongyu Qin , Siyu Shen , Haiqing Song , Hua Jiang , Chunxiang Zhang , Guozhi Xiao , Liping Tong , Qing Jiang , Di Chen

{"title":"Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma","authors":"Ke Lu , Ming Zhang , Hongyu Qin , Siyu Shen , Haiqing Song , Hua Jiang , Chunxiang Zhang , Guozhi Xiao , Liping Tong , Qing Jiang , Di Chen","doi":"10.1016/j.apsb.2024.03.013","DOIUrl":"10.1016/j.apsb.2024.03.013","url":null,"abstract":"<div><p>Cyclin D1 has been recognized as an oncogene due to its abnormal upregulation in different types of cancers. Here, we demonstrated that cyclin D1 is SUMOylated, and we identified Itch as a specific E3 ligase recognizing SUMOylated cyclin D1 and mediating SUMO-induced ubiquitination and proteasome degradation of cyclin D1. We generated cyclin D1 mutant mice with mutations in the SUMOylation site, phosphorylation site, or both sites of cyclin D1, and found that double mutant mice developed a Mantle cell lymphoma (MCL)-like phenotype. We showed that arsenic trioxide (ATO) enhances cyclin D1 SUMOylation-mediated degradation through inhibition of cyclin D1 deSUMOylation enzymes, leading to MCL cell apoptosis. Treatment of severe combined immunodeficiency (SCID) mice grafted with MCL cells with ATO resulted in a significant reduction in tumor growth. In this study, we provide novel insights into the mechanisms of MCL tumor development and cyclin D1 regulation and discover a new strategy for MCL treatment.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524000947/pdfft?md5=23e971a3ce9f0ceffceb96880d24fee1&pid=1-s2.0-S2211383524000947-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140125405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2 针对 SARS-CoV-2 中木瓜蛋白酶样蛋白酶的新型强效非共价小分子抑制剂的发现和表征

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.04.011

Miao Zheng , Bo Feng , Yumin Zhang , Xin Liu , Na Zhao , Hui Liu , Zichao Xu , Xinheng He , Zhiyan Qu , Shizhao Chen , Zhidong Jiang , Xi Cheng , Hong Liu , Yi Zang , Linxiang Zhao , Jie Zheng , Leike Zhang , Jia Li , Yu Zhou

引用次数: 0

Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway 非诺贝特促进的肝肿大和肝再生是 PPARα 依赖性的，并与 YAP 通路部分相关

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.030

Shicheng Fan , Yue Gao , Pengfei Zhao , Guomin Xie , Yanying Zhou , Xiao Yang , Xuan Li , Shuaishuai Zhang , Frank J. Gonzalez , Aijuan Qu , Min Huang , Huichang Bi

{"title":"Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway","authors":"Shicheng Fan , Yue Gao , Pengfei Zhao , Guomin Xie , Yanying Zhou , Xiao Yang , Xuan Li , Shuaishuai Zhang , Frank J. Gonzalez , Aijuan Qu , Min Huang , Huichang Bi","doi":"10.1016/j.apsb.2024.03.030","DOIUrl":"10.1016/j.apsb.2024.03.030","url":null,"abstract":"<div><p>Fenofibrate, a peroxisome proliferator-activated receptor <em>α</em> (PPAR<em>α</em>) agonist, is widely prescribed for hyperlipidemia management. Recent studies also showed that it has therapeutic potential in various liver diseases. However, its effects on hepatomegaly and liver regeneration and the involved mechanisms remain unclear. Here, the study showed that fenofibrate significantly promoted liver enlargement and regeneration post-partial hepatectomy in mice, which was dependent on hepatocyte-expressed PPAR<em>α</em>. Yes-associated protein (YAP) is pivotal in manipulating liver growth and regeneration. We further identified that fenofibrate activated YAP signaling by suppressing its K48-linked ubiquitination, promoting its K63-linked ubiquitination, and enhancing the interaction and transcriptional activity of the YAP–TEAD complex. Pharmacological inhibition of YAP–TEAD interaction using verteporfin or suppression of YAP using AAV <em>Yap</em> shRNA in mice significantly attenuated fenofibrate-induced hepatomegaly. Other factors, such as MYC, KRT23, RAS, and RHOA, might also participate in fenofibrate-promoted hepatomegaly and liver regeneration. These studies demonstrate that fenofibrate-promoted liver enlargement and regeneration are PPAR<em>α</em>-dependent and partially through activating the YAP signaling, with clinical implications of fenofibrate as a novel therapeutic agent for promoting liver regeneration.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524001230/pdfft?md5=8545325dc4c312649e8b61f5a4085c9f&pid=1-s2.0-S2211383524001230-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140407645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health 氨甲环酸及其主要靶标纤溶酶原在骨骼健康中的新作用

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.033

Weixin Xie, Antonia Donat, Shan Jiang, Anke Baranowsky, Johannes Keller

{"title":"The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health","authors":"Weixin Xie, Antonia Donat, Shan Jiang, Anke Baranowsky, Johannes Keller","doi":"10.1016/j.apsb.2024.03.033","DOIUrl":"10.1016/j.apsb.2024.03.033","url":null,"abstract":"<div><p>The worldwide burden of skeletal diseases such as osteoporosis, degenerative joint disease and impaired fracture healing is steadily increasing. Tranexamic acid (TXA), a plasminogen inhibitor and anti-fibrinolytic agent, is used to reduce bleeding with high effectiveness and safety in major surgical procedures. With its widespread clinical application, the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use. Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery. Also, several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing. Although a direct effect of TXA on the differentiation and function of bone cells <em>in vitro</em> was shown, few mechanisms of action have been reported. Here, we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and -independent mechanisms related to bone metabolism and the immune response. We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524001266/pdfft?md5=fb7d24686dae0594fff31274510710a5&pid=1-s2.0-S2211383524001266-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140404975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PIM1–HDAC2 axis modulates intestinal homeostasis through epigenetic modification PIM1-HDAC2 轴通过表观遗传修饰调节肠道稳态

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.04.017

Jianming Yang , Yawen Xiao , Ningning Zhao , Geng Pei , Yan Sun , Xinyu Sun , Kaiyuan Yu , Chunhui Miao , Ran Liu , Junqiang Lv , Hongyu Chu , Lu Zhou , Bangmao Wang , Zhi Yao , Quan Wang

{"title":"PIM1–HDAC2 axis modulates intestinal homeostasis through epigenetic modification","authors":"Jianming Yang , Yawen Xiao , Ningning Zhao , Geng Pei , Yan Sun , Xinyu Sun , Kaiyuan Yu , Chunhui Miao , Ran Liu , Junqiang Lv , Hongyu Chu , Lu Zhou , Bangmao Wang , Zhi Yao , Quan Wang","doi":"10.1016/j.apsb.2024.04.017","DOIUrl":"10.1016/j.apsb.2024.04.017","url":null,"abstract":"<div><p>The mucosal barrier is crucial for intestinal homeostasis, and goblet cells are essential for maintaining the mucosal barrier integrity. The proviral integration site for Moloney murine leukemia virus-1 (PIM1) kinase regulates multiple cellular functions, but its role in intestinal homeostasis during colitis is unknown. Here, we demonstrate that PIM1 is prominently elevated in the colonic epithelia of both ulcerative colitis patients and murine models, in the presence of intestinal microbiota. Epithelial PIM1 leads to decreased goblet cells, thus impairing resistance to colitis and colitis-associated colorectal cancer (CAC) in mice. Mechanistically, PIM1 modulates goblet cell differentiation through the Wnt and Notch signaling pathways. Interestingly, PIM1 interacts with histone deacetylase 2 (HDAC2) and downregulates its level <em>via</em> phosphorylation, thereby altering the epigenetic profiles of Wnt signaling pathway genes. Collectively, these findings investigate the unknown function of the PIM1–HDAC2 axis in goblet cell differentiation and ulcerative colitis/CAC pathogenesis, which points to the potential for PIM1-targeted therapies of ulcerative colitis and CAC.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524001588/pdfft?md5=029afe6211fdfb3b13090848b6450bbd&pid=1-s2.0-S2211383524001588-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140770860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease 单克隆抗体和适配体：阿尔茨海默病的未来疗法

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.034

Alvaro Barrera-Ocampo

{"title":"Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease","authors":"Alvaro Barrera-Ocampo","doi":"10.1016/j.apsb.2024.03.034","DOIUrl":"10.1016/j.apsb.2024.03.034","url":null,"abstract":"<div><p>Alzheimer's disease (AD) is considered the most common and prevalent form of dementia of adult-onset with characteristic progressive impairment in cognition and memory. The cure for AD has not been found yet and the treatments available until recently were only symptomatic. Regardless of multidisciplinary approaches and efforts made by pharmaceutical companies, it was only in the past two years that new drugs were approved for the treatment of the disease. Amyloid beta (A<em>β</em>) immunotherapy is at the core of this therapy, which is one of the most innovative approaches looking to change the course of AD. This technology is based on synthetic peptides or monoclonal antibodies (mAb) to reduce A<em>β</em> levels in the brain and slow down the advance of neurodegeneration. Hence, this article reviews the state of the art about AD neuropathogenesis, the traditional pharmacologic treatment, as well as the modern active and passive immunization describing approved drugs, and drug prototypes currently under investigation in different clinical trials. In addition, future perspectives on immunotherapeutic strategies for AD and the rise of the aptamer technology as a non-immunogenic alternative to curb the disease progression are discussed.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524001278/pdfft?md5=cc27694a2c2344ca18a30bd6e652d857&pid=1-s2.0-S2211383524001278-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140771248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-domain antibodies as therapeutics for solid tumor treatment 作为实体瘤治疗药物的单域抗体

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.03.016

Mingkai Wang , Tianlei Ying , Yanling Wu

{"title":"Single-domain antibodies as therapeutics for solid tumor treatment","authors":"Mingkai Wang , Tianlei Ying , Yanling Wu","doi":"10.1016/j.apsb.2024.03.016","DOIUrl":"10.1016/j.apsb.2024.03.016","url":null,"abstract":"<div><p>Single-domain antibodies (sdAbs), initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs, have emerged as a promising alternative to conventional therapeutic antibodies. These sdAbs have many superior physicochemical and pharmacological properties, including small size, good solubility and thermostability, easier accessible epitopes, and strong tissue penetration. However, the inherent challenges associated with the animal origin of sdAbs limit their clinical use. In recent years, various innovative humanization technologies, including complementarity-determining region (CDR) grafting or complete engineering of fully human sdAbs, have been developed to mitigate potential immunogenicity issues and enhance their compatibility. This review provides a comprehensive exploration of sdAbs, emphasizing their distinctive features and the progress in humanization methodologies. In addition, we provide an overview of the recent progress in developing drugs and therapeutic strategies based on sdAbs and their potential in solid tumor treatment, such as sdAb–drug conjugates, multispecific sdAbs, sdAb-based delivery systems, and sdAb-based cell therapy.</p></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":null,"pages":null},"PeriodicalIF":14.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211383524000984/pdfft?md5=7642d0cebe6f3d1ce84084b306b8b692&pid=1-s2.0-S2211383524000984-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140182150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antitumor activity and low gastrointestinal toxicity of a novel selective inhibitor of nuclear export, SZJK-0421, in multiple myeloma 新型核输出选择性抑制剂 SZJK-0421 在多发性骨髓瘤中的抗肿瘤活性和低胃肠道毒性

IF 14.7 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2024-07-01 DOI: 10.1016/j.apsb.2024.04.014

Jing Wang , Hang Miao , Xuxing Shen , Lin Yang , Yongqiang Zhu , Lijuan Chen

引用次数: 0